their unique vision for d3 bio is to create a bridge between insights about the actual clinical needs of patients and the scientific, biomarker-driven research needed to create precision medicines for the world.george chen, mdco-founder, chairman, & ceogeorge chen is an oncologist by training with a successful track record in the world of global pharmaceutical companies. prior to founding d3 bio, dr. chen held global senior executive positions in research, drug development and management at leading institutions, such as the national institutes of health, and multinational pharmaceutical companies, such as eli lilly, glaxosmithkline, johnson & johnson, beigene and astrazeneca. at these organizations he led development and regulatory registrations of blockbuster drugs into the u.s. and chinese markets, directing more than 70 ind approvals and more than 30 ndas. he receives his medical degree from the shanghai medical college of fudan university and his mba from the wharton school of business at the university of pennsylvania.john jin, phdco-founder, cfo, cbo, & board memberjohn jin was previously a founding partner at hanne capital and former vp of business development both at beigene and at taigen biotechnology (**). dr. jin had been responsible for venture investment, corporate and business development, government affairs, and global cross-border licensing deals for cancer and other drugs within china and internationally. during his early career, dr. jin took on various managerial roles at clearview projects, a us boutique strategic advisory firm, eli lilly and millennium pharmaceuticals. dr. jin has more than 20 years of experience in cross-border investment and financing, pharmaceutical business development and drug licensing, and research and development. dr. jin has a bachelor of medicine from peking university school of medicine, an mba from wharton school of business at the university of pennsylvania and a ph.d. in immunology from cornell university school of medicine.r&d pipelined3bio has built a pipeline of multiple pre-clinical stage oncology programs, all of which have first-in-class or best-in-class potential and carry foundational properties targeting immune-pathways or tumor driving mutations. d3 bio owns global rights to all the programs. d3bio policy on expanded access programin the newsmar 31, 2023d3 bio announces receiving an orphan drug designation and two ind clearances from fda for its compounds and presentation of pipeline data at upcoming aacr 2023 shanghai, china — d3 bio (wuxi) co. ltd (“d3 bio” or “the company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announces the…learn morenov 29, 2022 10:00 am estd3 bio’s d3s-001 receives u.s. fda fast track designation for the treatment of colorectal cancer with kras g12c mutationshanghai, china — d3 bio (wuxi) co. ltd (“d3 bio” or “company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announced that the u.s. food and drug administration (fda) has granted fast track designation (ftd) to d3s-001 for the treatment of advanced unresectable or metastatic colorectal cancers harboring kras g12c mutation that have...learn morenov 7, 2022 08:00 am estd3 bio announces data presentations at the society for immunotherapy of cancer 2022shanghai, china—d3 bio (wuxi) co. ltd (“d3 bio” or “company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announced the company’s new research data of its oncology program d3l-001 to be presented at the society for immunotherapy of cancer 2022 (sitc 2022) in boston, usa. those data highlight d3 bio’s pipeline innovations in cancer treatment.